Seeking Alpha

TheStreetSweeper sets sights on Sangamo BioSciences

  • Anyone who owns Sangamo BioSciences (SGMO), might want to take a trip over to TheStreetSweeper and check out their piece entitled "A fiery biotech with a product poised to go down in flames?"
  • The article questions the company's ZFN gene modification technology which is behind SB-728-T (see recent announcement of new data from Phase 2 trial).
  • Senior investigative reporter Sonya Colberg says "TheStreetSweeper would be astounded if SGMO produces a marketable anti-HIV product — ever."
  • Notably, Colberg also says "renowned HIV doctor" Joseph Sonnabend was consulted for the article and after reviewing "trial results and graphs," concluded that "no meaningful evidence was presented to indicate that [SGMO's] treatment has antiviral activity."
  • See also: SGMO offers shares
From other sites
Comments (3)
  • podell2
    , contributor
    Comments (7) | Send Message
     
    Cute little hit piece.
    I am long on SGMO (but can be somewhat complacent as I boughtin about 4.5)

     

    Richard Podell, M.D.

     

    Whether the technology will work or not is still to be determined. All we can say for now is that the HIV studies have looked at very few people so far, and what they've found so far is somewhat encouraging.

     

    A few people have been able to go without HIV meds for a few weeks without HIV appearing. Adding the treatment to current meds seems to improve T cell counts in the few people tested.

     

    Question: Why is Sangamo working with such a small number of patients. I'll guess that they're still trying to improve the yield on their techniques.

     

    Meanwhile they are attracting some interest from partners to create drugs for several monogenetic diseases. To the degree they can get big pharma to pay for their research, then they have time to build up a pipeline without running out of $.

     

    In theory, we should be surprised if the zinc finger technology doesn't work at least for those conditions where you can deliver treatment directly to the cells that need changing.

     

    Isis' anti-sense technology is effective at turning off targeted genes, and they've built a huge pipeline using mainly funds from big pharma. SGMO has proved it can insert or take out specific genes in animals. No doubt there are all sorts of practical obstacles to doing the same for people, but solving those problems is what we hope pharma scientists are good at.
    20 Sep 2013, 12:58 AM Reply Like
  • MineMan
    , contributor
    Comments (405) | Send Message
     
    Calling Dr Soonabend a renowned HIV scientist is as stretch.
    I doubt that he has a grasp of Sangamo Biosciences IP.
    PH I trials did what PH I trials are designed to do. Established dosages and protocols for the PH II trials.
    Safety cannot be denied. SGMO trials have NEVER shown any AEs or off target problems.
    I suggest this is just a paid assassin attempt to provide short position to buy before some big event causes the PPS to leap $5 over night.
    people seem to ignore the fact that several Funds thought that $10,58 per share was a reasonable price to pay for 7 million shares.. WHY? Why at this time?
    IMO, infamous would describe Dr Sonnabend better that renowned.
    Time will tell.
    20 Sep 2013, 08:16 AM Reply Like
  • screener2009
    , contributor
    Comments (2) | Send Message
     
    " "renowned HIV doctor" Joseph Sonnabend "
    Before deciding, you must GOOGLE Dr. Sonnabend. He retired 19 years ago and was considered a Quack back then by most of his peers. He was not renowned 20 years ago and anyone using him as an expert today is pathetic.
    20 Sep 2013, 08:36 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs